Galectin Therapeutics earnings were -$26.4M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest GALT earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$5.1M, down 8.9% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, GALT reported annual earnings of -$31.0M, with -34.4% growth. The next GALT earnings date is Aug 13, 2026.
Galectin Therapeutics Earnings Reports & History FAQ
What were Galectin Therapeutics's earnings last quarter?
Galectin Therapeutics (NASDAQ: GALT) reported Q1 2026 earnings per share (EPS) of -$0.08, up 46.67% year over year. Total GALT earnings for the quarter were -$5.07 million. In the same quarter last year, Galectin Therapeutics's earnings per share (EPS) was -$0.15.
The next GALT earnings call is Invalid Date. Add GALT to your watchlist to be reminded of Galectin Therapeutics's next earnings date.
Is Galectin Therapeutics profitable or losing money?
As of the last Galectin Therapeutics earnings report, Galectin Therapeutics is currently losing money. Galectin Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$26.25 million, a 41.91% decrease year over year.
What was GALT's earnings growth in the past year?
As of Galectin Therapeutics's earnings date in Q3 2026, Galectin Therapeutics's earnings has grown year over year. GALT earnings in the past year totalled -$26.44 million.
What are Galectin Therapeutics's earnings expectations?
The current EPS estimate for Galectin Therapeutics's earnings report in Invalid Date is -$0.09.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.